Cholesterol and the Risk of Grade-specific Prostate Cancer Incidence: Evidence from Two Large Prospective Cohort Studies with Up to 37 Years' Follow Up
Overview
Affiliations
Background: High cholesterol may be a modifiable risk factor for prostate cancer but results have been inconsistent and subject to potential "reverse causality" where undetected disease modifies cholesterol prior to diagnosis.
Methods: We conducted a prospective cohort study of 12,926 men who were enrolled in the Midspan studies between 1970 and 1976 and followed up to 31st December 2007. We used Cox-Proportional Hazards Models to evaluate the association between baseline plasma cholesterol and Gleason grade-specific prostate cancer incidence. We excluded cancers detected within at least 5 years of cholesterol assay.
Results: 650 men developed prostate cancer in up to 37 years' follow-up. Baseline plasma cholesterol was positively associated with hazard of high grade (Gleason score≥8) prostate cancer incidence (n = 119). The association was greatest among men in the 2nd highest quintile for cholesterol, 6.1 to < 6.69 mmol/l, Hazard Ratio 2.28, 95% CI 1.27 to 4.10, compared with the baseline of < 5.05 mmol/l. This association remained significant after adjustment for body mass index, smoking and socioeconomic status.
Conclusions: Men with higher cholesterol are at greater risk of developing high-grade prostate cancer but not overall risk of prostate cancer. Interventions to minimise metabolic risk factors may have a role in reducing incidence of aggressive prostate cancer.
Wu Z, Yang J, Ma Z, Chen Y, Han M, Wu Q J Gastroenterol. 2025; .
PMID: 40074913 DOI: 10.1007/s00535-025-02237-9.
Squalene monooxygenase (SQLE) protects ovarian cancer cells from ferroptosis.
Zhang R, Zhang L, Fan S, Wang L, Wang B, Wang L Sci Rep. 2024; 14(1):22646.
PMID: 39349544 PMC: 11442994. DOI: 10.1038/s41598-024-72506-9.
Cholesterol Metabolism and Urinary System Tumors.
Yang S, Ye Z, Ning J, Wang P, Zhou X, Li W Biomedicines. 2024; 12(8).
PMID: 39200296 PMC: 11351655. DOI: 10.3390/biomedicines12081832.
Martinovic A, Axon D Diseases. 2024; 12(6).
PMID: 38920552 PMC: 11202576. DOI: 10.3390/diseases12060120.
Vialat M, Baabdaty E, Trousson A, Kocer A, Lobaccaro J, Baron S Cancers (Basel). 2024; 16(11).
PMID: 38893271 PMC: 11172085. DOI: 10.3390/cancers16112153.